Your browser doesn't support javascript.
loading
Methylation of dual-specificity phosphatase 4 controls cell differentiation.
Su, Hairui; Jiang, Ming; Senevirathne, Chamara; Aluri, Srinivas; Zhang, Tuo; Guo, Han; Xavier-Ferrucio, Juliana; Jin, Shuiling; Tran, Ngoc-Tung; Liu, Szu-Mam; Sun, Chiao-Wang; Zhu, Yongxia; Zhao, Qing; Chen, Yuling; Cable, LouAnn; Shen, Yudao; Liu, Jing; Qu, Cheng-Kui; Han, Xiaosi; Klug, Christopher A; Bhatia, Ravi; Chen, Yabing; Nimer, Stephen D; Zheng, Y George; Iancu-Rubin, Camelia; Jin, Jian; Deng, Haiteng; Krause, Diane S; Xiang, Jenny; Verma, Amit; Luo, Minkui; Zhao, Xinyang.
Afiliação
  • Su H; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Jiang M; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Program of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA.
  • Senevirathne C; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • Aluri S; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.
  • Zhang T; Genomics and Epigenomics Core Facility, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA.
  • Guo H; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • Xavier-Ferrucio J; Department of Laboratory Medicine, Yale Stem Cell Center, Yale School of Medicine, New Haven, CT 06520, USA.
  • Jin S; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Tran NT; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Liu SM; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Sun CW; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Zhu Y; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • Zhao Q; Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Chen Y; Department of School of Life Sciences, Tsinghua University, Beijing 100084, China.
  • Cable L; Array BioPharma, Boulder, CO 80301 USA.
  • Shen Y; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Liu J; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Qu CK; Aflac Cancer and Blood Disorders Center, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • Han X; Department of Neurology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Klug CA; Department of Microbiology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Bhatia R; Division of Hematology and Oncology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Chen Y; Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA; Veterans Affairs Birmingham Medical Center, Research Department, Birmingham, AL 35294, USA.
  • Nimer SD; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33146 USA.
  • Zheng YG; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA.
  • Iancu-Rubin C; Department of Medicine, Hematology and Oncology Division, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Jin J; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Deng H; Department of School of Life Sciences, Tsinghua University, Beijing 100084, China.
  • Krause DS; Department of Laboratory Medicine, Yale Stem Cell Center, Yale School of Medicine, New Haven, CT 06520, USA.
  • Xiang J; Genomics and Epigenomics Core Facility, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA.
  • Verma A; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA. Electronic address: amit.verma@einsteinmed.org.
  • Luo M; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Program of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA. Electronic address: luom@mskcc.org.
  • Zhao X; Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: zhaox88@uab.edu.
Cell Rep ; 36(4): 109421, 2021 07 27.
Article em En | MEDLINE | ID: mdl-34320342
ABSTRACT
Mitogen-activated protein kinases (MAPKs) are inactivated by dual-specificity phosphatases (DUSPs), the activities of which are tightly regulated during cell differentiation. Using knockdown screening and single-cell transcriptional analysis, we demonstrate that DUSP4 is the phosphatase that specifically inactivates p38 kinase to promote megakaryocyte (Mk) differentiation. Mechanistically, PRMT1-mediated methylation of DUSP4 triggers its ubiquitinylation by an E3 ligase HUWE1. Interestingly, the mechanistic axis of the DUSP4 degradation and p38 activation is also associated with a transcriptional signature of immune activation in Mk cells. In the context of thrombocytopenia observed in myelodysplastic syndrome (MDS), we demonstrate that high levels of p38 MAPK and PRMT1 are associated with low platelet counts and adverse prognosis, while pharmacological inhibition of p38 MAPK or PRMT1 stimulates megakaryopoiesis. These findings provide mechanistic insights into the role of the PRMT1-DUSP4-p38 axis on Mk differentiation and present a strategy for treatment of thrombocytopenia associated with MDS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Megacariócitos / Diferenciação Celular / Fosfatases da Proteína Quinase Ativada por Mitógeno / Fosfatases de Especificidade Dupla Tipo de estudo: Prognostic_studies Limite: Adult / Animals / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Megacariócitos / Diferenciação Celular / Fosfatases da Proteína Quinase Ativada por Mitógeno / Fosfatases de Especificidade Dupla Tipo de estudo: Prognostic_studies Limite: Adult / Animals / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article